-
1.发明公开公开(公告)号：US20240358831A1
公开(公告)日：2024-10-31
申请号：US18685736
申请日：2022-08-24
IPC分类号： A61K39/00 , C07K14/74 , C12N5/0783
CPC分类号： A61K39/4632 , A61K39/4611 , C07K14/70539 , C12N5/0636 , C12N2502/11
摘要： The present invention relates to a method for selecting an immune cell expressing on its surface an antigen-binding protein specifically binding to a complex of a peptide A (PA) and a Major Histocompatibility Complex (MHC) molecule, comprising the steps of (i) providing a plurality of immune cells expressing different antigen-binding proteins; (ii) contacting the plurality of immune cells with a first composition comprising a complex 1A, comprising a MHC molecule 1 (M1) and a peptide A (PA), and a complex 1X, comprising M1 and a peptide B (PB); (iii) contacting the plurality of immune cells with a second composition comprising a complex 2A, comprising a MHC molecule 2 (M2) and PA, and a complex 2X, comprising M2 and a peptide C (PC); (iv) selecting from the plurality of immune cells a cell expressing an antigen binding protein that specifically binds to complex 1A, wherein complexes 1X and 2X, but not 1A and 2A, dissociate upon stimulation with a defined chemical or physical stimulus; and wherein the amino acid sequences of PB and PC differ in at least one amino acid. The invention further relates to an immune cell selected by the method according to the invention, a method of treatment using said immune cell, a kit for selecting a cell expressing on its surface an antigen-binding protein, and a peptide suitable for use in the method according to the invention.
-
公开(公告)号：US12121572B2
公开(公告)日：2024-10-22
申请号：US17502185
申请日：2021-10-15
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US12097248B2
公开(公告)日：2024-09-24
申请号：US17508230
申请日：2021-10-22
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US12084486B2
公开(公告)日：2024-09-10
申请号：US17472290
申请日：2021-09-10
发明人： Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh , Gisela Schimmack , Michael Roemer
IPC分类号： C07K14/725 , A61K9/19 , A61K35/17 , A61K38/00 , A61K39/00 , A61P35/00 , C07K14/74 , C07K16/28 , C12N5/0783 , C12N15/115 , G01N33/574 , G16B25/10
CPC分类号： C07K14/7051 , A61K9/19 , A61K35/17 , A61K39/001111 , A61P35/00 , C07K14/70539 , C07K16/2809 , C07K16/2833 , C12N5/0638 , C12N15/115 , G01N33/57492 , G16B25/10 , A61K38/00 , C07K2319/00 , C12N2310/16
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
5.发明公开公开(公告)号：US20240294602A1
公开(公告)日：2024-09-05
申请号：US18647837
申请日：2024-04-26
发明人： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC分类号： C07K14/74 , A01N37/46 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/17 , A61K39/00 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/725 , C07K16/18 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N9/64 , C12Q1/6886 , G01N33/50 , G01N33/566 , G01N33/569
CPC分类号： C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/04 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
摘要： A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
公开(公告)号：US12076381B2
公开(公告)日：2024-09-03
申请号：US17576185
申请日：2022-01-14
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
CPC分类号： A61K39/0011 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N5/0636 , C12N15/115 , C12Q1/6886 , G01N33/5748 , G01N33/6848 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2310/16 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N2570/00 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20240239867A1
公开(公告)日：2024-07-18
申请号：US18433955
申请日：2024-02-06
发明人： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC分类号： C07K14/725 , A61K35/17 , A61K38/00 , C07K14/74 , C07K16/28
CPC分类号： C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00 , C07K2319/30
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US12029785B2
公开(公告)日：2024-07-09
申请号：US17675530
申请日：2022-02-18
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： A61K39/00 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574
CPC分类号： A61K39/0011 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K16/3076 , C12N5/0636 , C12N15/115 , C12Q1/6886 , G01N33/57492 , A61K39/00 , A61K2039/5158 , C07K2319/40 , C12N2310/16 , C12N2501/50 , C12Q2600/106 , C12Q2600/156 , G01N2333/70539
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20240218044A1
公开(公告)日：2024-07-04
申请号：US18421973
申请日：2024-01-24
发明人： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC分类号： C07K14/725 , A61K35/17 , A61K38/00 , C07K14/74 , C07K16/28
CPC分类号： C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00 , C07K2319/30
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
10.发明授权公开(公告)号：US11999774B2
公开(公告)日：2024-06-04
申请号：US17314668
申请日：2021-05-07
发明人： Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K16/00 , A61K35/17 , A61K39/00 , C07K14/47 , C07K14/635 , C07K14/725 , C07K14/74 , C07K16/28 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61K38/00
CPC分类号： C07K14/70539 , A61K35/17 , A61K39/0011 , C07K14/4748 , C07K14/635 , C07K14/7051 , C07K16/2833 , C12N5/0638 , C12Q1/6886 , G01N33/57484 , A61K38/00 , A61K39/00 , C07K2319/70 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
1120 条记录 (耗时 0.049 秒)
